DaVita (BSP:DVAI34) Common Stock : R$0 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is DaVita Common Stock?

DaVita's quarterly common stock increased from Jun. 2023 (R$0 Mil) to Sep. 2023 (R$0 Mil) but then declined from Sep. 2023 (R$0 Mil) to Dec. 2023 (R$0 Mil).

DaVita's annual common stock declined from Dec. 2021 (R$1 Mil) to Dec. 2022 (R$0 Mil) and declined from Dec. 2022 (R$0 Mil) to Dec. 2023 (R$0 Mil).

DaVita Common Stock Historical Data

The historical data trend for DaVita's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Common Stock Chart

DaVita Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.52

0.57

0.55

0.47

0.44

DaVita Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															0.47	0.47	0.44	0.45	0.44

DaVita Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

DaVita (BSP:DVAI34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

DVA:USA TRL:Germany

Address

2000 16th Street, Denver, CO, USA, 80202

Website

https://www.davita.com

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

DaVita (BSP:DVAI34) Headlines

No Headlines